Jaguar health to present at lytham partners spring 2023 investor conference & participate in animal health panel

Jaguar animal health's canalevia®-ca1 is the first and only treatment for chemotherapy-induced diarrhea (cid) in dogs to receive fda conditional approval and is widely available through prominent pet retailers in the u.s. san francisco, ca / accesswire / may 16, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced that on thursday, may 18, 2023 lisa conte, jaguar's president, founder, and ceo, will present at the virtual lytham partners spring 2023 investor conference and take part in an animal health panel discussion during the event. company webcast the company's webcast presentation will be available for online viewing at 9:00 a.m.
JAGX Ratings Summary
JAGX Quant Ranking